{"organizations": [], "uuid": "d3ccd95834c378de0832a8c8215d28afb0140edf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biofrontera-12-month-follow-up-res/brief-biofrontera-12-month-follow-up-results-of-phase-iii-trial-for-daylight-pdt-idUSFWN1PI178", "country": "US", "domain_rank": 408, "title": "BRIEF-Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.217, "site_type": "news", "published": "2018-01-24T01:22:00.000+02:00", "replies_count": 0, "uuid": "d3ccd95834c378de0832a8c8215d28afb0140edf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biofrontera-12-month-follow-up-res/brief-biofrontera-12-month-follow-up-results-of-phase-iii-trial-for-daylight-pdt-idUSFWN1PI178", "ord_in_thread": 0, "title": "BRIEF-Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biofrontera ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - BIOFRONTERA AG:\n* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT\n* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY\n* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T01:22:00.000+02:00", "crawled": "2018-01-24T15:30:31.001+02:00", "highlightTitle": ""}